Advair Medication Guide FAQ
Here are answers to frequently asked questions about the Advair Diskus Medication Guide. Click a question below to see the answer.
I received an Advair Diskus Medication Guide (U.S. FDA Bulletins) when I picked up my Advair prescription from the pharmacy, should I be concerned?
Click here for the Advair Diskus Medication Guide.
You should read the Advair Diskus Medication Guide regarding Advair Diskus in order to familiarize yourself with drug and in particular to become familiar with the following section:
“Call your healthcare provider if :
- your breathing worsens with Advair Diskus
- you need to use your short-acting beta2-agonist medicine more often than usual
- your short-acting beta2-agonist medicine does not work as well for you at relieving symptoms
- you need to use 4 or more inhalations of your short-acting beta2-agonist medicine for 2 or more days in a row
- you use 1 whole canister of your short-acting beta2-agonist* medicine in 8 weeks’ time
- your peak flow meter results decrease. Your healthcare provider will tell you the numbers that are right for you.
- you have asthma and your symptoms do not improve after using Advair Diskus regularly for 1 week.”
*Note: For most patients the short-acting beta2-agonist medicine noted above is albuterol or the brand Proventil-HFA.
Why do I need to make an appointment to see the doctor four times a year if I am using Advair Diskus?
It is our present practice is to see all of our patients who are on Advair, Salmeterol or Foradil at least four times a year routinely in order to monitor their asthma and adjust medications as needed.
How can I tell how well my asthma is controlled?
We suggest that take a simple test to determine the level of your present asthma control by going to the following website: http://www.asthmacontrol.com.
What is the death rate for patients on Salmeterol in the “large asthma study” cited in the Advair Diskus Medication Guide?
Regarding the “large asthma study” which is known as the SMART study, referred to on the printed medication guide, the death rate for the group on the salmeterol component of Advair was approximately 0.1% (13/13,000) and for the placebo group 0.03% (3/13,000). However, of those patients treated with a combination of inhaled steroids and a long acting beta agonist (such as the Advair preparation) the death rate was similar between the placebo group (3 deaths) and the treated group (4 deaths.) The literature now suggests that the use of such combination therapy is not associated with significant increased risk. Risk is further minimized by careful monitoring of asthma status as described above.